Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irinotecan sucrosofate - Ipsen/Servier

Drug Profile

Irinotecan sucrosofate - Ipsen/Servier

Alternative Names: Irinotecan liposome injection - Merrimack; MM-398; nal-IRI; Nano-irinotecan; Nanoliposomal irinotecan - Merrimack/PharmaEngine; Nanoliposomal irinotecan injection - Merrimack/PharmaEngine; Onivyde; pegylated liposomal irinotecan hydrochloride trihydrate; PEP-02; SHP-673

Latest Information Update: 15 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HERMES BioSciences
  • Developer AIO Studien gGmbH; Emory University; Ipsen; Medica Scientia Innovation Research; Merrimack Pharmaceuticals; PharmaEngine; Rhode Island Hospital; Servier; Shire; Taiho Pharmaceutical; University of California at San Francisco; University of Florida
  • Class Alkaloids; Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pancreatic cancer
  • Phase II/III Small cell lung cancer
  • Phase II Biliary cancer; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer
  • Phase I/II Gastrointestinal cancer; Glioblastoma
  • No development reported Glioma; Solid tumours

Most Recent Events

  • 21 Jan 2019 PharmaEngine plans a phase I trial for Solid tumours (Combination therapy; Second-line therapy or greater) in January 2019(NCT03810742)
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 01 Nov 2018 Launched for Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Canada (IV) before November 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top